GLP-1 Receptor Agonists: A Research Primer
Semaglutide, tirzepatide, retatrutide — how the latest generation of incretin peptides differ.
Incretin biology is one of the most active research areas in metabolic science. This primer reviews how single-, dual-, and triple-receptor agonists differ in mechanism.
Single-receptor agonists
Semaglutide is the most-studied long-acting GLP-1 mono-agonist in current research literature.
Dual GIP/GLP-1 agonists
Tirzepatide adds GIP receptor activity, producing different downstream signalling profiles in research models.
Triple agonists
Retatrutide adds glucagon receptor activity and represents the current research frontier.
For research use only
Content in the Thrive Peptides journal summarizes published research and is intended for qualified investigators. It is not medical advice and does not describe products for human consumption.
Products discussed in this article
Dual GIP/GLP-1 receptor agonist for incretin pathway research.
Triple agonist (GIP/GLP-1/glucagon) used in next-generation metabolic studies.
Continue reading
Peptide Handling 101: Reconstitution, Storage, and Stability
A practical primer for research labs receiving lyophilized peptides for the first time.
BPC-157: A Practical Overview of the Current Research Landscape
What the literature says — and doesn't say — about BPC-157 in cellular repair and gastrointestinal models.
Copper Peptides and Fibroblast Research: What GHK-Cu Studies Show
The tripeptide that won't stay out of the cosmetic-science literature.